Actinogen Medical is pleased to announce the release of its September 2025 quarterly activity report and Appendix 4C. Key highlights include the acceleration of enrolment in the XanaMIA phase 2b/3 AD trial, with an updated timeline for final results in mid Q4 2026. The interim analysis for the trial remains on-track for late January 2026. A successful meeting with the FDA on the Alzheimer's program and the completion of a clinical pharmacokinetic trial for Xanamem were achieved. The company launched its Investor Hub site to provide shareholders with key updates and encourage engagement through Q&A. Manufacturing progress was made with the import of drug substance to the US for scaled-up tablet production. Additionally, ongoing initiatives include commercial planning, partnering discussions, strengthening IP protection, and preparations for a phase 3 trial and ancillary clinical studies. Financially, the company received funding from the R&D tax incentive (RDTI) and maintains a cash runway to mid-2026. The Company has a proforma cash position of $12.4m and has the potential to access additional funding in the short to medium-term from exercise of unlisted (3.75 cents) and listed (5.00 cents) stock options, future co-development partnerships and borrowing against its FY26 RDTI.

Actinogen continues to focus on late-stage clinical development of oral Xanamem for Alzheimer's disease - designed to position Xanamem as the leading next-generation therapy in the field. The company encourages investors to visit the Investor Hub for more information and invites questions to engage with the leadership team.

To join a webinar discussing recent progress, upcoming milestones and participate in a live Q&A session please see the related announcement today or register via pasting this link into your browser: https://actinogenmedical.zoom.us/webinar/register/WN_L_TOuTmaR4qYvYnXrNzfDQ